

Adherium Investor Webinar Replay

Melbourne, Australia – 24 February 2026: [Adherium Limited](#) (ASX:ADR), a global leader in digital respiratory management and developer of the FDA-cleared Hailie® Smartinhaler® platform is pleased to invite investors to access a recording of the live webinar held last week.

During the webinar, Adherium CEO, Dawn Bitz discussed:

Commercial progress

- The growth and momentum in Adherium's remote patient monitoring (RPM) channel as RPM device shipments rose from 351 shipments in Q4 FY2025 to 2,149 in Q2 FY2026 and RPM revenue increased from \$50.8k in Q4 FY2025 to \$171.0k in Q2 FY2026.
- How the RPM commercialisation is designed to underpin the next stage of growth for Adherium – enabling larger, value-based contracts with US insurers

Interim landmark ICARE Study Data

- Interim iCARE Study data demonstrated adherence rates of 64% in asthma patients and 67% COPD patients that use the Hailie® Smartinhalers™, representing a significant improvement from baseline adherence levels of approximately 20%.
- How this improvement translates to potential significant economic and patient outcomes for the healthcare system.
- Data from the landmark iCARE study accepted for publication and presentation at the American Thoracic Society 2026 International conference (ATS 2026), which takes place from 15-20 May 2026

Capital

- The capital raise announced on 16 February 2026 and completed on 18 February 2026 successfully received commitments of approximately \$6.70m. The retail offer is expected to open on 23 February 2026, proposing to raise up to \$0.82m to raise a total of \$7.52m under the Offer.

The presentation was followed by a Q+A session. Adherium thanks all those investors who attended the session.

To view a copy of the recording, please visit this link:

<https://www.adherium.com/news/investor-webinar-replay/>



ASX Release

- ENDS -

This ASX announcement was approved and authorised for release by the Board of Adherium.

Investor Enquiries

Adherium Limited
investors@adherium.com

Media Enquiries:

Haley Chartres
HACK Director
haley@hck.digital

About Adherium (ASX: ADR):

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. Learn more at adherium.com